Combining two precision medicines can treat drug-resistant cancers
Launching a dual-pronged attack on tumours using a combination of two innovative precision medicines could treat patients with multiple common cancers, a new clinical trial shows. It is the first trial to use the pioneering genetically targeted drug olaparib – already licensed for ovarian, breast and prostate cancer – together with a promising new medicine,…